샘플 요청 목록

 카트 문의
시장보고서
상품코드
2148435

간암 치료제 시장

Liver Cancer Drugs
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 391 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,953,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,110,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,859,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 간암 치료제 시장은 2032년까지 129억 달러에 달할 것으로 전망

2025년 42억 달러로 추정되는 세계 간암 치료제 시장은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 17.4%를 기록하며 2032년까지 129억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석 대상으로 삼고 있는 부문 중 하나인 ‘표적 치료’는 연평균 성장률(CAGR) 15.6%를 기록하며, 분석 기간이 끝날 때까지 44억 달러에 달할 것으로 예측됩니다. 또한, ‘면역 치료’ 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 15.2%를 나타낼 것으로 추정됩니다.

미국 시장은 11억 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 22.1%를 나타낼 것으로 예측됩니다.

2025년 미국의 간암 치료제 시장은 11억 달러로 추산됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 22.1%를 기록하며 2032년까지 시장 규모가 29억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 13.4% 및 15.8%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 13.9%를 나타낼 것으로 예측됩니다.

간암 치료제 - 주요 동향 및 촉진요인

간암 치료제에는 간세포암(HCC) 및 기타 간 악성 종양의 치료를 목적으로 하는 다양한 치료 옵션이 포함됩니다. 원발성 간암 중 가장 흔한 유형인 HCC는 B형 및 C형 간염, 비알코올성 지방간염(NASH), 간경변증 등의 만성 간 질환을 배경으로 발병하는 경우가 많습니다. 간 기능은 복잡하며 체내 대사 과정에서 매우 중요한 역할을 하기 때문에 간암 치료 환경에는 전통적으로 많은 과제가 있었습니다. 수술이나 경동맥 화학색전술(TACE)과 같은 국소 치료법을 포함한 기존의 접근 방식에 더해, 전신 치료법이 등장했습니다. 소라페닙이나 렌바티닙과 같은 표적 치료제는 종양의 증식 및 혈관 신생에 관여하는 특정 경로를 억제함으로써 진행성 간암 치료에 필수적인 역할을 해왔습니다. 이러한 약물은 생존율을 현저히 향상시켰지만, 환자의 삶의 질에 영향을 미칠 수 있는 심각한 부작용을 동반하는 경우도 적지 않습니다.

최근 몇 년간 면역요법이 간암 치료의 획기적인 접근법으로 부상했습니다. 펨브롤리주맙이나 니볼마브와 같은 면역관문억제제는 암세포에 대한 신체의 면역 반응을 강화한다는 점에서 유망하게 평가받고 있습니다. 이러한 치료법은 면역계 활동을 억제하는 단백질을 차단함으로써 작용하며, 이를 통해 T세포가 암세포를 더 효과적으로 공격할 수 있게 합니다. 또한, 면역요법과 표적요법 및 기타 치료법을 결합한 병용요법이 임상시험에서 적극적으로 검토되고 있습니다. 예를 들어, 아테졸리주맙과 베바시주맙의 병용은 기존의 단일제 요법에 비해 치료 성과의 개선이 나타났습니다. 이러한 진전은 더욱 개인화되고 효과적인 치료 요법으로의 전환을 부각시키고 있으며, 이는 생존 기간의 연장뿐만 아니라 간암 환자의 전반적인 삶의 질 향상도 목표로 하고 있습니다.

간암 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 특히 간염 감염이나 NASH(비알코올성 지방간염) 유병률이 높은 지역에서 간암 발생률이 증가하고 있어, 효과적인 치료법에 대한 수요가 높아지고 있습니다. 둘째, 신약 개발 및 유전체 연구 분야의 기술적 진보로 인해 새로운 치료 표적의 발견과 더 효과적인 약물의 개발이 촉진되고 있습니다. 셋째, 면역요법 및 표적 치료의 성공으로 인해 연구 개발에 대한 막대한 투자가 유치되며, 경쟁력이 있고 혁신적인 시장 환경이 조성되고 있습니다. 또한, 규제 당국이 획기적인 치료법에 대해 신속 승인을 실시하고 있어 환자에게 새로운 치료법을 제공하는 속도가 빨라지고 있습니다. 시너지 효과와 치료 성과 향상을 가져오는 병용 요법의 채택이 증가하고 있는 점도 시장 성장을 더욱 뒷받침하고 있습니다. 또한 조기 진단 및 첨단 치료법의 이점에 대한 의료 종사자와 환자의 인식이 높아짐에 따라 신약 채택률도 상승하고 있습니다. 마지막으로, 신흥국에서의 의료 인프라 확충과 첨단 의료에 대한 접근성 확대가 시장 성장의 새로운 기회를 창출하고 있어, 혁신적인 간암 치료법이 더 폭넓은 환자층에게 전달될 수 있게 되었습니다. 이러한 요인들이 복합적으로 작용하여 간암 치료제 시장의 강력한 확대와 역동적인 발전에 기여하고 있습니다.

부문:

치료법(표적 치료, 면역 치료, 화학 요법, 기타 치료법), 유형(간세포암, 담관암, 간모세포종, 기타 유형), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

주요 기업

  • 89bio
  • Alnylam Pharmaceuticals, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • CSPC Innovation Pharmaceutical
  • Double Bond Pharmaceutical
  • Eli Lilly and Company
  • Genoscience Pharma
  • Gilead Sciences, Inc.
  • Golden Biotechnology Corporation

해당 분야의 전문가 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.28

Global Liver Cancer Drugs Market to Reach US$12.9 Billion by 2032

The global market for Liver Cancer Drugs estimated at US$4.2 Billion in the year 2025, is expected to reach US$12.9 Billion by 2032, growing at a CAGR of 17.4% over the analysis period 2025-2032. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 15.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 22.1% CAGR

The Liver Cancer Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2032 trailing a CAGR of 22.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.4% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Liver Cancer Drugs - Key Trends and Drivers

Liver cancer drugs encompass a diverse range of therapeutic options aimed at treating hepatocellular carcinoma (HCC) and other malignancies of the liver. HCC, the most common type of primary liver cancer, often develops in the context of chronic liver diseases such as hepatitis B and C infections, non-alcoholic steatohepatitis (NASH), and cirrhosis. The treatment landscape for liver cancer has historically been challenging due to the complexity of the liver’s function and its vital role in the body’s metabolic processes. Traditional approaches, including surgery and localized therapies like transarterial chemoembolization (TACE), have been complemented by the advent of systemic treatments. Targeted therapies, such as sorafenib and lenvatinib, have been integral in managing advanced liver cancer by inhibiting specific pathways involved in tumor growth and angiogenesis. These drugs have provided significant survival benefits, although they are often associated with considerable side effects that can impact patients' quality of life.

In recent years, immunotherapy has emerged as a groundbreaking approach in the treatment of liver cancer. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown promise in enhancing the body’s immune response against cancer cells. These therapies work by blocking proteins that inhibit immune system activity, thus allowing T-cells to attack cancer cells more effectively. Additionally, combination therapies that integrate immunotherapies with targeted treatments or other modalities are being actively explored in clinical trials. The combination of atezolizumab and bevacizumab, for example, has demonstrated improved outcomes compared to traditional monotherapies. These advancements underscore a shift towards more personalized and effective treatment regimens, which not only aim to extend survival but also improve the overall quality of life for patients with liver cancer.

The growth in the liver cancer drugs market is driven by several factors. Firstly, the rising incidence of liver cancer, particularly in regions with high prevalence of hepatitis infections and NASH, has increased the demand for effective treatments. Secondly, technological advancements in drug development and genomic research have facilitated the discovery of novel therapeutic targets and the development of more effective drugs. Thirdly, the success of immunotherapies and targeted therapies has attracted significant investment in research and development, fostering a competitive and innovative market environment. Additionally regulatory agencies are providing accelerated approvals for breakthrough therapies, which helps expedite the availability of new treatments to patients. The increasing adoption of combination therapies, which offer synergistic effects and improved outcomes, further drives market growth. Furthermore, heightened awareness among healthcare providers and patients about the benefits of early diagnosis and advanced treatment options has led to a higher adoption rate of new drugs. Lastly, the expansion of healthcare infrastructure and access to advanced medical treatments in emerging economies is creating new opportunities for market growth, ensuring that innovative liver cancer therapies reach a broader patient population. These factors collectively contribute to the robust expansion and dynamic evolution of the liver cancer drugs market.

SCOPE OF STUDY:

The report analyzes the Liver Cancer Drugs market by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies); Type (Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type, Other Types); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • 89bio
  • Alnylam Pharmaceuticals, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • CSPC Innovation Pharmaceutical
  • Double Bond Pharmaceutical
  • Eli Lilly and Company
  • Genoscience Pharma
  • Gilead Sciences, Inc.
  • Golden Biotechnology Corporation

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Liver Cancer Drugs - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 52 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Liver Cancer Expands Addressable Market Opportunity
    • Advances in Immunotherapy Throws the Spotlight on Novel Treatment Approaches
    • Rising Geriatric Population Strengthens Business Case for Liver Cancer Drugs
    • Enhanced Drug Delivery Systems Drives Adoption of Liver Cancer Drugs
    • Increasing Awareness and Early Diagnosis Spurs Growth in Treatment Demand
    • Technological Innovations in Drug Development Generates New Market Opportunities
    • Robust Pipeline of Liver Cancer Drugs Boost Future Market Growth
    • Rising Healthcare Expenditure Sustains Growth of Liver Cancer Treatment Market
    • Combination Therapies Expand Treatment Options and Market Potential
    • Personalized Treatment Plans Enhance Treatment Efficacy and Market Demand
    • Improved Patient Outcomes Generates Confidence in Liver Cancer Drug Market
    • Increasing Use of Biomarkers and Genomics Expands Addressable Market Opportunity
    • Market Penetration in Emerging Economies Fuel Growth Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Liver Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Hepatocellular Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Hepatocellular Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Hepatocellular Carcinoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Cholangio Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Cholangio Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Cholangio Carcinoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Hepatoblastoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Hepatoblastoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Hepatoblastoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 41: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 44: USA Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Canada Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Canada 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • JAPAN
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Japan Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: Japan 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • CHINA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 68: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 71: China Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: China Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: China 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • EUROPE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Liver Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Europe Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: Europe 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • FRANCE
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 89: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 92: France Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: France Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: France 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • GERMANY
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Germany Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Germany 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Italy Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Italy 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 116: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 119: UK Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: UK Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: UK 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Spain Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Spain 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Spain Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Spain 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Spain Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Spain 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Russia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Russia 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Russia Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Russia 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Russia Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Russia 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of Europe 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of Europe 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Rest of Europe 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Liver Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Australia Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Australia 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Australia Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Australia 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Australia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Australia 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • INDIA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: India Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: India 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 173: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: India Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: India 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
    • TABLE 176: India Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: India Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: India 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: South Korea Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: South Korea 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: South Korea Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: South Korea 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: South Korea Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: South Korea 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Liver Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Latin America Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Latin America 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Latin America Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Latin America 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Argentina Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Argentina 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Argentina Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Argentina 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Argentina Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Argentina 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Brazil Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Brazil 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Brazil Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Brazil 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Brazil Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Brazil 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Mexico Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Mexico 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Mexico Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Mexico 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Mexico Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Mexico 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Latin America 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Latin America 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Latin America 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Liver Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Liver Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Middle East Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Middle East 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Middle East Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Middle East 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Iran Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Iran 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Iran Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Iran 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Iran Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Iran 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Israel Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Israel 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Israel Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Israel 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Israel Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Israel 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Saudi Arabia 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Saudi Arabia 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Saudi Arabia 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: UAE Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: UAE 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: UAE Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: UAE 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: UAE Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: UAE 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Rest of Middle East 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Rest of Middle East 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Rest of Middle East 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032
  • AFRICA
    • Liver Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Africa Historic Review for Liver Cancer Drugs by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Africa 13-Year Perspective for Liver Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Distribution Channel for the Years 2020, 2026 & 2032
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Africa Historic Review for Liver Cancer Drugs by Therapy - Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Africa 13-Year Perspective for Liver Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy, Chemotherapy and Other Therapies for the Years 2020, 2026 & 2032
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Africa Historic Review for Liver Cancer Drugs by Type - Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Africa 13-Year Perspective for Liver Cancer Drugs by Type - Percentage Breakdown of Value Sales for Hepatocellular Carcinoma Type, Cholangio Carcinoma Type, Hepatoblastoma Type and Other Types for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기